hsa-miR-204

ncRNA information

ncRNA name

hsa-miR-204

Specific or universal ncRNAs

Specific ncRNAs

Class

MicroRNA

Biomarker

No

Biomarker application

Upstream regulatory factors

Not available

Downstream target

FAP-Ī±

Cancer information

Cancer name

Glioblastoma

Cancer site

Brain, Central Nervous System

Treatment information

Treatment type

Chemotherapy

Drug

Temozolomide

Impact of wild-type ncRNA on chemotherapy resistance

Down

Impact of knockdown of ncRNA on chemotherapy resistance

Impact of overexpression of ncRNA on chemotherapy resistance

Clinical Information

ncRNA differential expression in
cancer patients vs. healthy people

Not available

Number of patients

Not available

Male patients

Not available

Female patients

Not available

Age range and number

Not available

Research information

PMID

Description

It was concluded that miR-204 reversed temozolomide resistance and inhibited CICs phenotypes by degrading FAP-Ī± in glioblastoma.

Tissue resource

glioblastoma tissues

glioblastoma cell lines U251MG

Experiment

qRT-PCR,Western blot


Institute

Beijing Chaoyang Hospital

the Institute of Biochemistry and Cell Biology Institute of Shanghai, Chinese Academy of Sciences

Country

China

Continent

Asia